Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $9.80.

Several equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, January 28th. Finally, Craig Hallum initiated coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target on the stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. grew its position in shares of Aclaris Therapeutics by 2.2% in the 3rd quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock valued at $539,000 after buying an additional 6,217 shares during the last quarter. Rhumbline Advisers raised its position in shares of Aclaris Therapeutics by 7.4% during the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 6,271 shares during the last quarter. ProShare Advisors LLC raised its position in shares of Aclaris Therapeutics by 45.4% during the fourth quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 6,734 shares during the last quarter. Intech Investment Management LLC lifted its stake in shares of Aclaris Therapeutics by 19.8% in the fourth quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 7,702 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of Aclaris Therapeutics by 59.0% in the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 9,894 shares during the period. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Down 5.7%

Shares of ACRS opened at $3.66 on Friday. The stock has a market cap of $441.40 million, a PE ratio of -6.91 and a beta of 0.88. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $4.89. The business has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $2.75.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million. On average, equities research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.